Statistical Analysis Relapse-free survival represented the primary clinical endpoint.

It is often used as a clinical endpoint in randomized controlled trials for cancer therapies.

Ideal discrimination of discrete clinical endpoints using multilocus genotypes.

A beneficial effect on hard clinical endpoints has been more difficult to prove.

Most of these trials did not achieve statistically significant improvements in their clinical endpoints.

If a clinical endpoint is devastating enough (e.g. death, heart attack), drugs with a low absolute risk reduction may still be indicated in particular situations.

In a general sense, a clinical endpoint is included in the entities of interest in a trial.

For example, a clinical trial investigating the ability of a medication to prevent heart attack might use chest pain as a clinical endpoint.

Many drugs may be abandoned due to their failure to meet a clinical endpoint.

Trials that rely solely on clinical endpoints are very costly as they have long durations and tend to need large number of patients.